Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus NORQUEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus NORQUEST FE.
ENOVID-E vs NORQUEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Category C
Category C
Oral Contraceptive
Oral Contraceptive